[HTML][HTML] The impacts of prophylactic anticoagulation therapy during hospitalization on long-term cardiovascular outcomes in high-risk COVID-19 patients amid the …
J Gu, Y Wang, J Zhang, C Wang - IJC Heart & Vasculature, 2024 - Elsevier
Background Although prophylactic anticoagulation therapy is suggested to be adopted in
severe COVID-19 patients, its effects on the long-term cardiovascular (CV) outcomes …
severe COVID-19 patients, its effects on the long-term cardiovascular (CV) outcomes …
[HTML][HTML] Electrolytes, Zinc and Vitamin D 3 in COVID-19 Patients with Cardiovascular Complications
AAMMH AlKhuzaie… - Problems of …, 2024 - virusjour.crie.ru
Introduction. COVID-19 is strongly linked to cardiovascular disease, with direct myocardial
injury and systemic inflammation as common mechanisms. Pre-existing or infection-induced …
injury and systemic inflammation as common mechanisms. Pre-existing or infection-induced …
O uso dos Anticoagulantes Orais de Ação Direta (DOACs) como terapia anticoagulante na COVID-19
EM Sousa, GEF Neto, HM Lobo… - Revista Eletrônica …, 2024 - acervomais.com.br
Objetivo: Identificar os efeitos da utilização dos Anticoagulantes Orais de Ação Direta
(DOACs) na infecção pelo SARS-CoV-2 como terapia anticoagulante no curso da doença …
(DOACs) na infecção pelo SARS-CoV-2 como terapia anticoagulante no curso da doença …